Research programme: anti-tropomyosin therapeutics - Kazia Therapeutics
Alternative Names: Anisina; Anti-tropomyosins - Kazia Therapeutics; ATM drugs - Kazia Therapeutics; ATM-3507; Tm5NM1 protein inhibitors - Kazia Therapeutics; Tpm3.1 protein inhibitors - Kazia Therapeutics; TR 100Latest Information Update: 28 Jul 2019
At a glance
- Originator Genscreen; University of New South Wales
- Developer Kazia Therapeutics; Nationwide Children's Hospital
- Class Small molecules
- Mechanism of Action Tropomyosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Neuroblastoma; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Prostate-cancer in Australia (IV)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Malignant-melanoma in Australia (IV)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neuroblastoma in Australia (IV)